Skip to main content
SpringerLink
Log in

Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P < 0.001; overall survival (OS), 42.2 months vs. not reached, P = 0.001]. On multivariate analysis, PET/CT positivity was significantly associated with PFS and OS in patients with RI. In conclusion, PET/CT is a reliable imaging technique for predicting survival outcomes in patients with MM with RI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

    Article  PubMed  Google Scholar 

  2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.

    Article  PubMed  Google Scholar 

  3. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337–41.

    Article  CAS  PubMed  Google Scholar 

  4. Davenport A, Merlini G. Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrol Dial Transplant. 2012;27:3713–8.

    Article  PubMed  Google Scholar 

  5. Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, et al. Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. results from the Australia and New Zealand myeloma and related diseases registry. Clin Lymphoma Myeloma Leuk. 2019;19:e415–24.

    Article  PubMed  Google Scholar 

  6. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976–84.

    Article  PubMed  Google Scholar 

  7. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91:854–9.

    Article  CAS  PubMed  Google Scholar 

  8. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219–26.

    Article  PubMed  Google Scholar 

  9. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423–9.

    Article  CAS  PubMed  Google Scholar 

  10. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195–200.

    Article  CAS  PubMed  Google Scholar 

  11. Jung SH, Cho MS, Kim HK, Kim SJ, Kim K, Cheong JW, et al. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. BMC Cancer. 2016;16:613.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J. 2017;7:e571.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206–17.

    Article  PubMed  Google Scholar 

  15. Jung SH, Kwon SY, Min JJ, Bom HS, Ahn SY, Jung SY, et al. (18)F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. Eur J Nucl Med Mol Imaging. 2019;46:107–15.

    Article  PubMed  Google Scholar 

  16. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089–100.

    Article  PubMed  Google Scholar 

  17. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.

    Article  PubMed  Google Scholar 

  18. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.

    Article  CAS  PubMed  Google Scholar 

  20. Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007;21:217–22.

    Article  CAS  PubMed  Google Scholar 

  21. Akers SR, Werner TJ, Rubello D, Alavi A, Cheng G. 18F-FDG uptake and clearance in patients with compromised renal function. Nucl Med Commun. 2016;37:825–32.

    Article  CAS  PubMed  Google Scholar 

  22. Kode V, Karsch H, Osman MM, Muzaffar R. Impact of renal failure on F18-FDG PET/CT scans. Front Oncol. 2017;7:155.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.

    Article  CAS  PubMed  Google Scholar 

  24. Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, et al. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function. Ann Oncol. 2012;23:722–9.

    Article  CAS  PubMed  Google Scholar 

  25. Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99:148–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dimopoulos M, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 2019;133:147–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, et al. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol. 2017;92:1280–6.

    Article  CAS  PubMed  Google Scholar 

  29. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102:593–9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea

    Seo-Yeon Ahn, Hwa Kyung Park, Ga-Young Song, Deok-Hwan Yang, Jae-Sook Ahn, Hyeoung-Joon Kim, Sung-Hoon Jung & Je-Jung Lee

  2. Department of Hematology-Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea

    Joon Ho Moon, Dong Won Baek, Hee-Jeong Cho & Sang Kyun Sohn

  3. Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea

    Sae-Ryung Kang, Jung-Joon Min & Hee-Seung Bom

  4. Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea

    Chae Moon Hong

  5. Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea

    Shin Young Jeong

Authors
  1. Seo-Yeon Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hwa Kyung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joon Ho Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dong Won Baek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hee-Jeong Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sang Kyun Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sae-Ryung Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jung-Joon Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hee-Seung Bom
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chae Moon Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shin Young Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ga-Young Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Deok-Hwan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jae-Sook Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hyeoung-Joon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Sung-Hoon Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Je-Jung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SHJ and JJL designed the study and HKP and SHJ prepared the manuscript; SRK, JJM, HSB, CMH, SYJ performed the image analysis; JHM, DWB, HJC, SKS, SYA, GYS, DHY, JSA and HJK critically reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Sung-Hoon Jung.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahn, SY., Park, H.K., Moon, J.H. et al. Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. Int J Hematol 113, 668–674 (2021). https://doi.org/10.1007/s12185-021-03079-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-021-03079-w

Keywords

Search

Navigation